The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd

CTL/SAST/26-27/01194 13 August 2026 1. Department of Corporate Services, BSE Limited Floor 25, P J Towers, Dalal Street, Mumbai - 400 001 2. National Stock Exchange of lndia Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 3. cc: Dr. Agarwal’s Health Care Limited 1st Floor, Buhari Towers, No. 4, Moores Road, off Greams Road, Near Asan Memorial School, Chennai, Tamil Nadu 600006 Sub: Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dear Sir/Ma’am, We, Catalyst Trusteeship Limited (“Onshore Security Agent”), write in our capacity as a pledgee for the Shares (as defined below) of Dr. Agarwal’s Health Care Limited (“Target Company”). A facility agreement dated March 26, 2024 (“Facility Agreement”) had been entered into between, inter alia, Hyperion Investments Pte. Ltd. (“Borrower”) and certain lenders for the purpose of availing a facility aggregating up to USD 100,000,000 (“Facility”) by the Borrower. The Borrower had pledged 73,193,988 equity shares of the issued and paid-up share capital of the Target Company (“Shares”) in favour of the Onshore Security Agent, through the depository system. The Onshore Security Agent had previously made a disclosure on 6 February 2025 under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (the “Takeover Code”), in relation to the Target Company, as more particularly described therein as well as herein below. Enclosed is a disclosure under Regulation 29 (2) of the Takeover Code for the release of encumbrance over 31,698,303 equity shares of the Company. We request you to take the same on record and acknowledge the same. Yours faithfully, For Catalyst Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: 13 August 2026 Disclosure under Regulation 29(2) of SEBl (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Name of the Target Company Dr. Agarwal’s Health Care Limited (TC) Name(s) of the acquirer and Catalyst Trusteeship Limited acting in its capacity as the Persons Acting in Concert (PAC) onshore security agent for certain lenders to Hyperion with the acquirer Investments Pte. Ltd. under the Facility Agreement (as defined below Whether the acquirer belongs to No Promoter/Promoter group Name(s) of the Stock BSE Limited and National Stock Exchange of India Limited Exchange(s) where the shares of TC are Listed % w .r.t. % w.r.t. total total diluted share/voting Details of the share/voting Number capital acquisition/disposal as follows capital of the wherever applicable(*) (**) Before the acquisition/ Nil Nil Nil disposal under consideration, holding of: (a) Shares carrying voting rights (b) Shares in the nature of 73,193,988# 23.09# 22.93# encumbrance (pledge/ lien/ non-disposal undertaking/ others) (c) Voting rights (VR) Nil Nil Nil otherwise than by equity shares (d) Warrants/convertible Nil Nil Nil securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) (e) Total (a+b+c+d) 73,193,988# 23.09# 22.93# Details of acquisition/sale/disposal (a) Shares carrying voting Nil Nil Nil rights acquired / sold (b) VRs acquired / sold Nil Nil Nil otherwise than by shares (c) Warrants/convertible Nil Nil Nil securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired / sold (d) Shares encumbered / 31,698,303# 10.00# 9.93# invoked / released by the acquirer (e) Total (a+b+c+/-d) 31,698,303# 10.00# 9.93# After the Nil Nil Nil acquisition/sale/disposal, holding of: (a) Shares carrying voting rights (b) Shares encumbered with 41,495,685# 13.09# 12.99# the acquirer (c) VRs otherwise than by Nil Nil Nil shares (d) Warrants/convertible Nil Nil Nil securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition (e) Total (a+b+c+d) 41,495,685# 13.09# 12.99# Mode of acquisition/sale (e.g. Partial release of encumbrance (created by way of pledge). open market / off-market / public Please see note # below. issue / rights issue / preferential allotment / inter se transfer etc.) Date of acquisition/ sale of 11 August 2026 (date of partial release of pledge) shares/ VR or date of receipt of intimation of allotment of shares, whichever is applicable. Equity share capital / total voting 316,983,028 fully paid up equity shares of INR 1/- each capital of the TC before the said acquisition / sale Equity share capital/ total voting 316,983,028 fully paid up equity shares of INR 1/- each capital of the TC after the said acquisition / sale Total diluted share/voting capital 319,262,876 fully paid up equity shares of INR 1/- each of the TC after the said acquisition / sale Note # 1. A facility agreement dated March 26, 2024 (“Facility Agreement”) had been entered into between, inter alia, Hyperion Investments Pte. Ltd. (“Borrower”) and certain lenders for the purpose of availing a facility aggregating up to USD 100,000,000 (“Facility”) by the Borrower. The Borrower had pledged 73,193,988 equity shares of the issued and paid-up share capital of the Target Company (“Shares”) in favour of the Onshore Security Agent, through the depository system. 2. Disclosure under Regulation 29(1) of the Takeover Code had been made with respect to this transaction by the Onshore Security Agent on 6 February 2025. 3. The pledge over 31,698,303 Shares was released on 11 August 2026. 4. In terms of Regulation 29(2) read with Regulation 29(4) of the Takeover Code, shares that are given up on release of encumbrance (by way of pledge) shall be treated as a disposal. Accordingly, this disclosure is being made in respect of the release of encumbrance created over the Shares in favour of the Onshore Security Agent for the benefit of the relevant lenders. For Catalyst Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: 13 August 2026 Note: (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.